2022-10-25| Trials & Approvals

Bristol Myers Squibb’s Ulcerative Colitis Treatment Gains Further Validation

by Max Heirich
Share To

Bristol Myers Squibb (BMS) announced an analysis of its Phase 3 True North study evaluating the duration of response following Zeposia (ozanimod) treatment continued for up to a year. Although approved in both the United States and the European Union, the True North program aims to evaluate the continued use of Zeposia in active ulcerative colitis.

Related Article: FDA Pushes Biogen’s ALS Drug Approval Date Back Three Months

The Ulcerative Colitis Treatment and Other Uses

Ulcerative colitis is a chronic inflammatory bowel which causes inflammation and ulcers within a patient’s digestive tract. Though currently, the direct cause is not understood, factors like an abnormal immune response, genetics, microbiome, and environmental factors play a part in the disease’s development. 

While there is no direct cure, there are a number of treatments available that help patients mitigate the symptoms as well as assist in preventing life-threatening complications from arising. Among these treatments is BMS’ Zeposia.

Zeposia gained approval from the United States Food and Drug Administration (FDA) in May of 2021, with approval from the European Commission following in November of that year. The drug treats ulcerative colitis through the reduction of certain white blood cells (lymphocytes) in the lymph nodes, resulting in a reduction of inflammation. This mechanism of action also works for the treatment of multiple sclerosis, for which the FDA granted approval for Zeposia’s treatment in 2020.

Though having already gained approval, BMS initiated the True North clinical trial program with the goal of analyzing the duration of response following continuous Zeposia (ozanimod) treatment for up to one year. Overall, approximately 86.1% of patients remaining on Zeposia showed no sign of disease relapse after a year.

On the data presented, Bruce E. Sands, MD, MS, Gastroenterologist and paid consultant of Bristol Myers Squibb, said, “Understanding the duration of response after continuous ozanimod treatment is critical, as it can assist in clinical decision making when considering temporary discontinuation of UC treatment in clinical practice. These analyses reaffirm that ozanimodtreatment is effective at helping patients remain relapse-free and suggest that a majority of patients remain relapse-free for up to eight weeks after treatment is interrupted.”

Despite the results reinforce Zeposia’s efficacy in treating ulcerative colitis, BMS is not done with the treatment just yet. The Phase 3 YELLOWSTONE clinical trial is currently evaluating the usage of Zeposia in treating Crohn’s Disease. With an end date set in early 2024, any results, as well as any potential approval, remain to be seen. 

© All rights reserved. Collaborate with us:
Related Post
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
GeneOnline’s Pick: Top 10 M&A Deals in 2022
Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
First Human Trial for Marburg Virus Vaccine Reports Success
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!